Drug Trial Radar · NCT03388125
Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection
Last checked: Nov 20, 2026Latest source record: Apr 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
113
Actual
Start
Jan 1, 2016
Primary completion
Aug 1, 2017
Study completion Dec 1, 2022
Sponsor
- Lead sponsor
- Sherief Abd-ElsalamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Endoscopic Injection Sclerotherapy vs N-butyl-2-cyanoacrylate Injection
Conditions
- Bleeding Esophageal Varices
Interventions
Injection SclerotherapyDrug
5% ethanolamine oleate group
N-butyl-2-cyanoacrylateDrug
N-butyl-2-cyanoacrylate injection group
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with controlled bleedingTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sherief Abd-Elsalam
Tanta, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.